<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281058</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000699</org_study_id>
    <nct_id>NCT02281058</nct_id>
  </id_info>
  <brief_title>Open-label Pilot Study of Abatacept for the Treatment of Vitiligo</brief_title>
  <official_title>Open-label Pilot Study of Abatacept for the Treatment of Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are&#xD;
      performing a pilot study for the treatment of new onset or actively progressing vitiligo with&#xD;
      abatacept to determine if weekly self-injections of medication lead to clinical improvement&#xD;
      in vitiligo lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abatacept has been shown to decrease T cell activity and reduce symptoms associated with&#xD;
      rheumatoid arthritis. Similar pathways have been shown to be involved in vitiligo. Therefore,&#xD;
      we are recruiting 10 adult patients with active vitiligo who meet specific inclusion and&#xD;
      exclusion criteria to receive self-administered injections of abatacept weekly starting at&#xD;
      week 0 and continuing until week 24. A 32 week follow-up visit will be performed to evaluate&#xD;
      secondary endpoints as well. We will be monitoring patients to see if skin lesions of&#xD;
      vitiligo stop spreading and start to repigment with continued treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in repigmentation with abatacept therapy as measured using the Vitiligo Area and Severity Index (VASI) score</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical safety and rate of adverse events as measured by patient-reported side effects</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage repigmentation with abatacept therapy as measured using the physician's global assessment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on disease-related quality of life as measured using the validated Vitiligo Quality of Life (VitiQOL) tool</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maintenance of repigmentation after stopping therapy</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initial time to repigmentation</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>self-injected subcutaneous biologic medication</description>
    <arm_group_label>intervention group</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant individuals ages 18 and older with a diagnosis of actively progressive&#xD;
             skin lesions of clinically diagnosed vitiligo covering at 5% or great body surface&#xD;
             area (defined as development of new lesions or worsening of existing lesions within&#xD;
             the past 6 months) not receiving immune suppressive treatment. Both subjects who have&#xD;
             received at least one therapy in the past and subjects currently receiving treatment&#xD;
             at the time of screening will be eligible providing they undergo a wash out period&#xD;
             prior to starting the study (2 weeks for topical agents and systemic agents with short&#xD;
             half lives, 1 month for phototherapy)&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an acceptable method of&#xD;
             contraception to avoid pregnancy throughout the study and for up to 10 weeks after the&#xD;
             last dose of study drug in such a manner that the risk of pregnancy is minimized&#xD;
&#xD;
          -  WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity&#xD;
             25 IU/L or equivalent units of HCG) within 0 to 48 hours before the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Women must not be breast-feeding&#xD;
&#xD;
          -  Sexually active fertile men must use effective birth control if their partners are&#xD;
             WOCBP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding patients&#xD;
&#xD;
          -  Patients with segmental, acrofacial, or universal vitiligo&#xD;
&#xD;
          -  Patients with evidence of poliosis (white hairs) within the majority (&gt;50%) of their&#xD;
             vitiligo lesions&#xD;
&#xD;
          -  Patients currently on any other systemic biologic medication, current use of&#xD;
             Abatacept, or any other systemic biologic medication within 2 months of study (or&#xD;
             within 5 half-lives of last dose of drug)&#xD;
&#xD;
          -  Use of systemic immunosuppressive agent within 2 weeks prior to initiation of&#xD;
             Abatacept&#xD;
&#xD;
          -  Use of potent topical steroids, topical tacrolimus or pimecrolimus within 2 weeks&#xD;
             prior to initiation of Abatacept&#xD;
&#xD;
          -  Use of phototherapy within one month prior to initiation of Abatacept therapy&#xD;
&#xD;
          -  Patients with a history of chronic obstructive pulmonary disease&#xD;
&#xD;
          -  History of active Mycobacterium tuberculosis infection (any subspecies) Use of any&#xD;
             investigational medication within 28 days prior to enrollment or 5 half-lives if known&#xD;
             (whichever is longer)&#xD;
&#xD;
          -  Receiving concomitant immune modulating therapy (see concomitant medications, section&#xD;
             8.6). Subjects receiving such agents at screening may be eligible to enroll following&#xD;
             a washout period of 2 weeks for topical agents and systemic agents with short half&#xD;
             lives&#xD;
&#xD;
          -  Subjects who are impaired, incapacitated, or incapable of completing study-related&#xD;
             assessments&#xD;
&#xD;
          -  Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic,&#xD;
             hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease,&#xD;
             whether or not related to vitiligo and which, in the opinion of the investigator,&#xD;
             might place a subject at unacceptable risk for participation in the study&#xD;
&#xD;
          -  Subjects with a history of cancer in the last 5 years, other than non-melanoma skin&#xD;
             cell cancers cured by local resection or carcinoma in situ. Existing non-melanoma skin&#xD;
             cell cancers should be removed, the lesion site healed, and residual cancer ruled out&#xD;
             before administration of the study drug&#xD;
&#xD;
          -  Subjects who currently abuse drugs or alcohol&#xD;
&#xD;
          -  Subjects with evidence (as assessed by the investigator) of active or latent bacterial&#xD;
             or viral infections at the time of potential enrollment, including subjects with&#xD;
             evidence of human immunodeficiency virus (HIV) detected during screening.&#xD;
&#xD;
          -  Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months&#xD;
             before the informed consent document was signed&#xD;
&#xD;
          -  Subjects who have received any live vaccines within 3 months of the anticipated first&#xD;
             dose of study medication&#xD;
&#xD;
          -  Subjects with any serious bacterial infection within the last 3 months, unless treated&#xD;
             and resolved with antibiotics, or any chronic bacterial infection (eg, chronic&#xD;
             pyelonephritis, osteomyelitis, or bronchiectasis)&#xD;
&#xD;
          -  Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be&#xD;
             subjects with a history of active TB within the last 3 years, even if it was treated;&#xD;
             a history of active TB greater than 3 years ago, unless there is documentation that&#xD;
             the prior anti-TB treatment was appropriate in duration and type; current clinical,&#xD;
             radiographic, or laboratory evidence of active TB; and latent TB that was not&#xD;
             successfully treated (â‰¥ 4 weeks)&#xD;
&#xD;
          -  Subjects must not be positive for hepatitis B surface antigen&#xD;
&#xD;
          -  Subjects must not be positive for HIV&#xD;
&#xD;
          -  Subjects who are positive for hepatitis C antibody if the presence of hepatitis C&#xD;
             virus was also shown with polymerase chain reaction or recombinant immunoblot assay&#xD;
&#xD;
          -  Subjects with any of the following laboratory values Hemoglobin &lt; 8.5 g/dL WBC &lt;&#xD;
             3000/mm3 (&lt; 3 x 109/L) Platelets &lt; 100,000/mm3 (&lt; 3 x 109/L) Serum creatinine &gt; 2&#xD;
             times the ULN Serum ALT or AST &gt; 2 times the ULN&#xD;
&#xD;
          -  Any other laboratory test results that, in the opinion of the investigator, might&#xD;
             place a subject at unacceptable risk for participation in the study&#xD;
&#xD;
          -  Allergies to any components of abatacept or its vehicle&#xD;
&#xD;
          -  Subjects who have at any time received treatment with any investigational drug within&#xD;
             28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose&#xD;
&#xD;
          -  Any concomitant biologic DMARD, such as anakinra&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2014</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Victor Huang</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

